JPRN-UMIN000012705招募中未知
The efficacy and safety of an anti-interluekin-6 receptor antibody in relapsing-remitting multiple sclerosis - Treatment with an anti-interleukin-6 receptor antibody for relapsing-remitting multiple sclerosis
Department of Immunology, National Institute of Neuroscience, NCNP0 个研究点目标入组 10 人开始时间: 2014年1月7日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe infection such as tuberculosis, pneumocystis carinii pneumonia, nontuberculous mycobacterial infection, hepatitis B, hepatitis C, or chronic active EB virus infection. 2) Patients with a history of tuberculosis infection or patients with pleural thickness or old tuberculin in chest X-ray. 3) Patients with a history of hypersensitivity to this drug. 4) Patients with a history of intestinal diverticulum. 5) Patients with interstitial pneumonitis. 6) Patients with leukopenia (white blood cell number < 3500/mm3), lymphopenia (lymphocyte number < 500/mm3) or seropositivity for beta-D-glucan in peripheral blood. 7) Pregnant women or patients with possible pregnancy. 8) Patients with a history of allergy to this drug 9) Patients who can not provide consent to participate in this study by themselves.
研究者
相似试验
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of an antibody, which blocks the pro-inflammatory mediator Interleukin-6, in patients with late Antibody-mediated rejection of a transplanted kidney - A Pilot TrialAntibody-mediated rejection of a kidney transplantEUCTR2017-001604-30-DECharité Berlin20
进行中（未招募）
1 期
Safety, Tolerability and Efficacy of an antibody, which blocks the pro-inflammatory mediator Interleukin-6, in patients with late Antibody-mediated rejection of a transplanted kidney - A Pilot TrialAntibody-mediated rejection of a kidney transplantEUCTR2017-001604-30-ATMedical University of Vienna20
进行中（未招募）
1 期
Anti-il6 treatment of serious COVID-19 disease with threatening respiratory failureSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code 10070267Term: SARS virus test positiveSystem Organ Class: 100000004848EUCTR2020-001275-32-DKThe Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark200
进行中（未招募）
不适用
Evaluation effects of treatment with an inhibitor of the receptor of a protein (interleukin-6 IL-6)involved in inflammatory process, on the clinical response and on the changes from baseline in the biomarkers in patients with rheumatoid arthritis (RA)not responding adequately to Disease-modifying antirheumatic drugs (DMARDs) and/or to a first biological agent.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-001760-30-ITOSSERVATORIO EPIDEMIOLOGICO GISEA
已完成
不适用
Treatment with an anti-interleukin-6 receptor antibody for multiple sclerosisD009103multiple sclerosisJPRN-jRCTs031180346Yamamura Takashi6